Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664123 | 0.87 | GCGR (0.35) | — | |
| SCHEMBL5532894 | 0.84 | — | — | |
| SCHEMBL13664504 | 0.84 | — | — | |
| SCHEMBL14364516 | 0.81 | — | — | |
| SCHEMBL30699313 | 0.81 | PDE3B (0.38) | PDE5APDE4APDE1APDE1BPDE4B | |
| SCHEMBL4300317 | 0.81 | PDE3B (0.38) | PDE5APDE4APDE1APDE1BPDE4B | |
| SCHEMBL13664495 | 0.79 | TUBB1 (0.31) | — | |
| SCHEMBL4309431 | 0.79 | GAA (0.41) | — | |
| SCHEMBL13664201 | 0.74 | LMNA (0.34) | — | |
| SCHEMBL13662892 | 0.74 | TSHR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614316-B2 | Optically active quaternary ammonium salt having axial asymmetry and process for producing α-amino acid and derivative thereof with the same | NAGASE & CO., LTD. (JP) | 2013-12-24 | — | — | US | disclosed |
| EP-2484667-A1 | Optically active quaternary ammonium salt having axial asymmetry and process for producing alpha-amino acid and derivative thereof with the same | NAGASE & COMPANY, LTD. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| EP-1870403-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & COMPANY, LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| EP-1870403-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING -AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | NAGASE & COMPANY, LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270614-A1 | OPTICALLY ACTIVE QUATERNARY AMMONIUM SALT HAVING AXIAL ASYMMETRY AND PROCESS FOR PRODUCING ALPHA-AMINO ACID AND DERIVATIVE THEREOF WITH THE SAME | BCAT1, BCAT2, AADAT | PDE5A 4496/4885PDE4A 4574/4885PDE1A 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.